Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELENAGEN + Gemcitabine in Platinum-resistant Ovarian Cancer
NCT05979298Phase 2Completed
- Sponsor
- CureLab Oncology
- Start
- Nov 2019
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Elenagen in ovarian cancer (2 arms), sponsored by CureLab Oncology. Primary endpoint: Progression-free Survival at 2 years. Started Nov 2019; status: completed.
02
Drugs
Elenagen
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05979298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979298.